1 However, due to oxidation reaction in vivo,
no significant difference between (
64)Cu(I) and (64)Cu(I
2 Although there was
no significant difference between 8IU intranasal oxytoci
3 intranasal oxytocin compared to placebo, but
no significant difference between 8IU intranasal oxytoci
4 There were
no significant differences between ACHD and non-ACHD pat
5 lobal IBS symptoms at 4-12 weeks, there were
no significant differences between active treatments aft
6 There was
no significant difference between age groups in the rate
7 There was
no significant difference between all diets for C-reacti
8 There was
no significant difference between all diets on inflammat
9 were observed in mixed batch, and there was
no significant difference between aluminum and iron elec
10 ncreased in all three treatment groups, with
no significant difference between AMG 714 and placebo.
11 PERCIST5 (P = 0.5), respectively, indicating
no significant difference between analyzing the SUL(peak
12 No significant difference between antibiotics was demons
13 There were
no significant differences between any APO(a)-L(Rx) dose
14 change (80% at baseline vs 86% at 12 months;
no significant difference between arms) but the proporti
15 There were
no significant differences between arms for any secondar
16 le strength and in vitro cytotoxicity showed
no significant difference between AuNP-infused and untre
17 There were
no significant differences between basal, mid-, or apica
18 In the 1000cs oil group, there was
no significant difference between baseline IOP and any s
19 Additionally, although
no significant difference between beginner and advanced
20 lie in a narrow range similar to bone, with
no significant difference between benign and malignant.
21 No significant differences between BG-OG and DDG-OG or b
22 elial-derived EV than healthy subjects, with
no significant differences between BHD and mOL-HDF.
23 e heterogeneity should be deterministic with
no significant differences between biological replicates
24 PET using BKC showed
no significant difference between bioluminescence and en
25 We detected
no significant differences between bortezomib- and place
26 comparison with spectrophotometry, there are
no significant differences between both methods using a
27 Disinfection results showed
no significant differences between both processes, showi
28 There were
no significant differences between BP-SES and PP-EES.
29 fold change range: -0.423 to -0.987), while
no significant difference between cancer and stroma tiss
30 There was
no significant difference between case and control group
31 At baseline, there were
no significant differences between case and controls reg
32 o 300 minutes after vaporization; there were
no significant differences between CBD-dominant cannabis
33 No significant difference between changes in 12 months a
34 There was
no significant difference between ciclosporin and inflix
35 There were
no significant differences between closed-loop and contr
36 BOP, PD, and CAL compared to baseline, with
no significant difference between control and treatment
37 c study's semiquantitative analysis revealed
no significant differences between control and BPA dose
38 r of GelMA, movement of the cell front shows
no significant differences between control and EGF-stimu
39 umetric and DTI analysis measurements showed
no significant differences between control and Hdc KO mi
40 Histologically, there were
no significant differences between control and PHT, at a
41 Analysis of journal impact factor showed
no significant difference between correct and incorrect
42 Furthermore, there was
no significant difference between corresponding cycle th
43 o 0.6% for photon-counting detector CT, with
no significant differences between CT systems (P = .65).
44 , appearance, and inflammation, demonstrated
no significant differences between DBBM-C and control (n
45 No significant differences between DFT versus no-DFT coh
46 There were
no significant differences between diets for HDL cholest
47 GAARlandia land-bridge hypothesis, there was
no significant difference between distance-dependent mod
48 The primary analysis showed
no significant difference between eculizumab and placebo
49 nts with postinfectious hydrocephalus showed
no significant difference between endoscopic ETV-CPC and
50 e lower than that of CLN, but at 24 h it was
no significant difference between ENS and CLN.
51 No significant differences between ETDRS groups were fou
52 There was
no significant difference between exiting and nonexiting
53 ts with an elevated d-dimer level, there was
no significant difference between extended-duration betr
54 s showed a decrease in color intensity, with
no significant differences between fig and blackthorn ex
55 within 8 to 30 days (n = 27176), there were
no significant differences between follow-up at 2 months
56 There was
no significant difference between good adherence, poor a
57 eceived azithromycin in the first year, with
no significant difference between groups (P = 0.55).
58 7 patients (6.0%) in the Cryo-2 group, with
no significant difference between groups (P=0.24).
59 f 81 patients had cognitive impairment, with
no significant difference between groups (treatment effe
60 tched CRT-control pairs were identified with
no significant difference between groups across all base
61 At 52 weeks, we noted
no significant difference between groups for disease pro
62 There was
no significant difference between groups in GSH in eithe
63 for the primary endpoint, because there was
no significant difference between groups in mean daily b
64 for the primary endpoint, because there was
no significant difference between groups in mean daily b
65 There was
no significant difference between groups in the incidenc
66 There was
no significant difference between groups in the median c
67 There was
no significant difference between groups in withdrawal t
68 There was
no significant difference between groups over time in th
69 There was also
no significant difference between groups regarding the m
70 high-density lipoprotein cholesterol showed
no significant difference between groups with and withou
71 test and control groups, respectively, with
no significant difference between groups.
72 ents had severe adverse events but there was
no significant difference between groups.
73 , fitness, physical activity, and diet, with
no significant difference between groups.
74 : from 26.3 [SD=5.4] to 14.4 [SD=9.3]), with
no significant difference between groups.
75 utcome measure of functional cognition, with
no significant difference between groups.
76 There were
no significant differences between groups 1 and 2 in dem
77 There were
no significant differences between groups 1 and 2 in ref
78 aker/defibrillator implantation demonstrated
no significant differences between groups after adjustme
79 baseline and 6 months for both groups, with
no significant differences between groups at any follow-
80 rocessed by sHLD, dHLD, or HLD/ETO, we found
no significant differences between groups for MDRO or ba
81 At age 18 mo, there were
no significant differences between groups in any scores.
82 [95% CI, 0.87 to 1.09]; P = .62); there were
no significant differences between groups in depression
83 nt of much or very much in CGI-I score, with
no significant differences between groups in either clin
84 There were
no significant differences between groups in patients' g
85 There were
no significant differences between groups in proportions
86 There were
no significant differences between groups in proportions
87 However, there were
no significant differences between groups in proportions
88 with -0.017 points per month) and there were
no significant differences between groups in the frequen
89 Likewise, there were
no significant differences between groups in the seconda
90 There were
no significant differences between groups in time taken
91 There were
no significant differences between groups in time to ext
92 After the intervention, we observed
no significant differences between groups on early autis
93 We observed
no significant differences between groups on self-report
94 fore surgery, steep and flat keratometry had
no significant differences between groups, and at last f
95 ve (<1%) had gastrointestinal bleeding, with
no significant differences between groups.
96 e at 90 days) and adverse events, there were
no significant differences between groups.
97 TATION: For the primary outcomes, there were
no significant differences between groups.
98 However, there were
no significant differences between groups.
99 For motor abundance, there were
no significant differences between groups.
100 e of the pyrolysates was highly variable and
no significant difference between HA and FA was found fo
101 There were
no significant differences between high-dose and standar
102 y greater than of human serum, but there was
no significant difference between human and NWM sera.
103 There was
no significant difference between image quality of ADC a
104 Radiocarbon analysis showed overall
no significant difference between intact and burnt PSF w
105 Histopathological examination revealed
no significant difference between kidneys, whereas MALDI
106 There was
no significant difference between lanicemine and placebo
107 ) of subjects with HCV genotype 1 infection (
no significant difference between ledipasvir/sofosbuvir
108 rom 12 months to final follow-up), there was
no significant difference between MACE, death/MI, and in
109 , multivariable regression analysis revealed
no significant differences between MACH and GBAE implant
110 istered to deduce overall wellness, provided
no significant differences between males and females or
111 The study showed that there was
no significant difference between manufactured UDCA (cap
112 There were
no significant differences between matched patients rega
113 There was
no significant difference between mean ADC value of 12 l
114 However, there was
no significant difference between mean early PPG and lat
115 There were
no significant differences between men and women in thei
116 s vs individuals with epsilon3/epsilon4, but
no significant differences between men and women with ep
117 There was also
no significant difference between MI size3-slices and MI
118 Although there was
no significant difference between microplastic abundance
119 No significant difference between Mirococept at 10 mg an
120 se-shrinkage analysis showed that there were
no significant differences between model parameters for
121 Results There were
no significant differences between morning and afternoon
122 McNemar tests showed
no significant differences between MRI and dual-energy C
123 There is
no significant difference between MT4 and MSP for detect
124 There were
no significant differences between MTTT and CTTT (P = 0.
125 While there was
no significant difference between non-advanced AMD and n
126 There was
no significant difference between other complication rat
127 There was
no significant difference between patients using lower d
128 ir younger age at first diagnosis, there was
no significant difference between patients with or witho
129 There were
no significant differences between patients with IBD in
130 y-matched population of patients, there were
no significant differences between patients with ISR and
131 ntermediate anatomical complexity, there was
no significant difference between PCI and CABG with resp
132 These meta-analyses showed
no significant difference between performance of advance
133 t differences in clinical outcomes, and thus
no significant differences between polypill and comparat
134 s and 1, 2, and 4 weeks after surgery showed
no significant differences between PPC and CCC in cornea
135 There were
no significant differences between prasugrel and ticagre
136 In contrast, there were
no significant differences between pre-ATI and postinter
137 No significant differences between pre-exercise and reco
138 The model was well calibrated with
no significant difference between predicted and observed
139 There were
no significant differences between primary endpoint rate
140 ing over $10,000 in income during leave with
no significant difference between procedural and nonproc
141 There was
no significant difference between progressing and stable
142 There were
no significant differences between progression of vascul
143 There were
no significant differences between psychological interve
144 The null hypothesis of
no significant difference between pulse sequences was as
145 respectively, increased ICAD prevalence with
no significant differences between races.
146 There were
no significant differences between red meat and all comp
147 Bland-Altman analysis showed
no significant difference between ROI and segmentation m
148 No significant differences between sclerotherapy and cya
149 There were
no significant differences between sexes for scleritis i
150 There was
no significant difference between SI values measured in
151 There was
no significant difference between silicone oil microdrop
152 There were
no significant differences between standard TTS and prol
153 he third/fourth transplant group, there were
no significant differences between standard versus exten
154 We noted
no significant differences between statin users and non-
155 lthough task performance improved over days,
no significant difference between stimulation protocols
156 There were
no significant differences between studies with low vers
157 e level of the healthcare facility, we found
no significant difference between study arms for any eco
158 There was
no significant difference between study arms in 52-week
159 There was
no significant difference between study groups in the ra
160 in all clinical parameters (P < 0.05), with
no significant differences between study groups at all t
161 Spectral components of the EEG revealed
no significant differences between successful and unsucc
162 d survival compared with surgery alone, with
no significant difference between surgery-based multimod
163 RNase P gene control in the CDC assay showed
no significant differences between swabs for both gene t
164 The C(t) values showed
no significant differences between swabs for both viral
165 There were
no significant differences between TAVR and SAVR in any
166 There were
no significant differences between TAVR versus SAVR for
167 No significant difference between TBMES and osteonecrosi
168 igh vs lower initial white blood cell count,
no significant differences between TDT groups were obser
169 ath (4.4% vs. 0.6%, P=0.001), but there were
no significant differences between tenofovir-based ART a
170 There was
no significant difference between the 2 groups for 90-da
171 onths and 1 year after discharge also showed
no significant difference between the 2 groups of patien
172 However, there was
no significant difference between the 2 intervention arm
173 A and IDI, respectively); however, there was
no significant difference between the 2 intravitreal tre
174 Statistical analysis showed there was
no significant difference between the ability of the thr
175 There was
no significant difference between the accuracy of the re
176 There was
no significant difference between the ALD-401 and placeb
177 There was
no significant difference between the area under the cur
178 Interestingly, there was
no significant difference between the breadth of the res
179 llel analysis of 30 cancer patients, to find
no significant difference between the capture efficiency
180 As a result,
no significant difference between the charge transfer re
181 There was
no significant difference between the cohorts in the per
182 ess, and the results revealed that there was
no significant difference between the data sets obtained
183 There is
no significant difference between the effect of topical
184 At baseline, there was
no significant difference between the effective concentr
185 In intention-to-treat analysis, there was
no significant difference between the elafibranor and pl
186 There was
no significant difference between the erythropoietin gro
187 There was
no significant difference between the ETV-CPC group and
188 ngth for group 1 and 7.09% for group 2, with
no significant difference between the groups (P = .09).
189 d to pre-failure levels in both groups, with
no significant difference between the groups at any time
190 ed to prefailure levels in both groups, with
no significant difference between the groups at any time
191 ycemic control in both groups, and there was
no significant difference between the groups in glycated
192 There was
no significant difference between the groups in terms of
193 No significant difference between the groups was noted u
194 No significant difference between the groups was shown i
195 There was
no significant difference between the groups with respec
196 CI, 0.08 to 2.15) in the surgery group, with
no significant difference between the groups, and it dec
197 s per minute in the surgery group; there was
no significant difference between the groups.
198 cose and insulin levels in both groups, with
no significant difference between the groups.
199 We found
no significant difference between the high-dose IV iron
200 There was
no significant difference between the IB or TB conjuncti
201 There was
no significant difference between the IBU-alone group vs
202 At 30 days, there was
no significant difference between the intervention and c
203 There was
no significant difference between the intervention and u
204 There was
no significant difference between the levosimendan group
205 is (Fisher's exact test) indicated there was
no significant difference between the methods at the 99%
206 No significant difference between the microbiome of cats
207 ular involvement when compared with SJS, but
no significant difference between the number of moderate
208 There was
no significant difference between the observed and predi
209 There was
no significant difference between the patient group and
210 In an intention-to-treat analysis, there was
no significant difference between the pessary group (465
211 respectively; P = 0.042), whereas there was
no significant difference between the placebo trained an
212 There was
no significant difference between the rate of positive s
213 We found
no significant difference between the regions in the pos
214 coupled plasma mass spectrometric method and
no significant difference between the results was observ
215 There was
no significant difference between the sensitivity of the
216 Analysis demonstrated
no significant difference between the SGS group and the
217 There was
no significant difference between the study groups in th
218 There was
no significant difference between the study groups with
219 In a time-to-event analysis, we found
no significant difference between the supplemental-oxyge
220 However, there was
no significant difference between the treatment groups a
221 There was
no significant difference between the treatment groups i
222 However, there was
no significant difference between the trial groups eithe
223 n those in controls, whereas MICA*009 showed
no significant difference between the two groups (17.1%
224 change in both groups (p > 0.05) and showed
no significant difference between the two groups (p > 0.
225 There was
no significant difference between the two groups in OI a
226 group (-0.33 [-0.45 to -0.21] p<0.001), with
no significant difference between the two groups.
227 ion whereas the duration of vigilance showed
no significant difference between the two habitats.
228 (p<0.0001 for both groups vs placebo), with
no significant difference between the two seladelpar gro
229 There were
no significant differences between the 2 experimental gr
230 In comparisons of outcomes, we found
no significant differences between the 3-year vs 5-year
231 There were
no significant differences between the active and placeb
232 No significant differences between the antibiotic group
233 There were
no significant differences between the average number of
234 After propensity score matching, there were
no significant differences between the BL/D-C (110 patie
235 In our study there are
no significant differences between the different protoco
236 he drought-tolerant PFT; however, there were
no significant differences between the early- and late-s
237 There were
no significant differences between the ganciclovir and p
238 There were
no significant differences between the groups (hazard ra
239 of 18 complications occurred, but there were
no significant differences between the groups (P=0.21).
240 For secondary outcomes, there were
no significant differences between the groups for mean c
241 There were
no significant differences between the groups in acute a
242 There were
no significant differences between the groups in the inc
243 There were
no significant differences between the groups in the inc
244 There were
no significant differences between the groups in the rat
245 There were
no significant differences between the groups on any of
246 However, there were
no significant differences between the groups on cortiso
247 No significant differences between the groups were found
248 spectively, during clamp stage 2; there were
no significant differences between the groups.
249 At baseline there were
no significant differences between the groups.
250 At 6 months, there were
no significant differences between the injection (n = 38
251 There were
no significant differences between the intervention and
252 There also were
no significant differences between the intervention and
253 However, there were
no significant differences between the intervention arms
254 For DBP, there were
no significant differences between the intervention grou
255 patient safety climate), whereas there were
no significant differences between the intervention grou
256 There were
no significant differences between the levosimendan grou
257 We found
no significant differences between the number of lesions
258 There were
no significant differences between the randomisation gro
259 The qualitative analysis showed
no significant differences between the raw and the ferme
260 Paired t tests showed
no significant differences between the reference standar
261 There were
no significant differences between the results obtained
262 There were
no significant differences between the strain data obtai
263 There were
no significant differences between the strawberry and co
264 No significant differences between the treatment groups
265 No significant differences between the treatments were s
266 There were
no significant differences between the two groups for an
267 There were
no significant differences between the two groups in ter
268 There were
no significant differences between the two groups in the
269 There were
no significant differences between the two groups in the
270 There were
no significant differences between the two groups in var
271 There were
no significant differences between the two interventions
272 over a median of 3 years of follow-up, with
no significant differences between the two treatment gro
273 Paired t testing showed
no significant differences between the values obtained w
274 There were
no significant differences between the VATS and open app
275 There were
no significant differences between the visual acuity usi
276 There were
no significant differences between the vitamin C and pla
277 ther grade 3 or 4 toxicities were rare, with
no significant differences between the VTD and VCD arms.
278 No significant differences between these repeated measur
279 There was
no significant difference between this correlation at 3
280 Among patients undergoing CABG, there was
no significant difference between those receiving single
281 s fulfilled criteria for biliary colic, with
no significant difference between those with and without
282 Among AED-exposed children, there were
no significant differences between those with BDs and th
283 There was
no significant difference between thresholds in stressed
284 There was
no significant difference between treatment groups for t
285 There was
no significant difference between treatment groups in ch
286 nths with C25, and 5.3 months with D75, with
no significant differences between treatment arms.
287 There were also
no significant differences between treatment groups for
288 Similarly, at 16 weeks, there were
no significant differences between treatment groups in c
289 covering and HR for recovering also revealed
no significant differences between treatment groups in e
290 solids content decreased during storage with
no significant difference between treatments.
291 vastatin group had virological failure, with
no significant difference between treatments.
292 Pooled effect sizes showed
no significant difference between TRS and non-TRS studie
293 fluorescence retina nuclear layers disclosed
no significant differences between TT and any observer's
294 uary 1, 2009-December 31, 2013) demonstrated
no significant differences between VA centers, VA-affili
295 There were
no significant differences between verubecestat and plac
296 There were
no significant differences between vitamin D and placebo
297 In all but 1 of our comparisons,
no significant difference between wildtype and heterozyg
298 ct trials than correct trials, but there was
no significant difference between win and loss trials.
299 However, overall clinical outcome showed
no significant difference between women and men after 1
300 treatment effects may persist, as there were
no significant differences between WT and APP/PS1 mice a